Connect with us

Press Release

OncoCyte’s Innovative Approach: Potential in Precision Diagnostics

Published

on

–News Direct–

Chronic conditions such as organ transplant rejection and cancer represent significant challenges in modern healthcare, demanding precise diagnostic tools for effective management and treatment. For organ transplant patients, the risk of graft rejection remains a persistent threat, necessitating continuous monitoring to ensure long-term success. Similarly, the complexity of cancer requires advanced diagnostics to tailor treatments to individual patients, optimizing therapeutic efficacy while minimizing adverse effects.

Amidst these challenges, OncoCyte Corporation (NASDAQ: OCX) has emerged as an innovative player in the precision diagnostics market. The company's tests enhance clinical outcomes for patients undergoing organ transplants and cancer treatments. With recent strategic partnerships and regulatory advancements, OncoCyte has spearheaded transformative advancements in the field.

OCXs product portfolio includes VitaGraft, a clinical blood-based test for monitoring solid organ transplants, and GraftAssure, a research-use-only test for the same purpose. Additionally, DetermaIO and DetermaCNI are designed for oncology applications, predicting responses to immunotherapies and monitoring therapeutic efficacy, respectively.

Partnerships

In April 2024, OCX partnered with Bio-Rad Laboratories (NYSE: BIO) to commercialize the GraftAssure assay. This agreement leverages Bio-Rad's extensive reach and expertise in the life sciences sector, facilitating the co-marketing of GraftAssure in the U.S. and Germany. Bio-Rad holds exclusive global distribution rights outside these regions. This collaboration is pivotal for scaling OncoCyte's operations and meeting the growing demand for transplant diagnostics.

The partnership also includes an option for Bio-Rad to acquire IVD commercial rights upon FDA clearance, subject to specific milestones. This option comes with a second equity investment into OncoCyte, reflecting Bio-Rad's confidence in the product's market potential. Riggs noted, "The QX600 ddPCR platform, along with their expertise in the life science market, makes Bio-Rad a natural partner for our transplant technology."

Financial Performance

OncoCyte's Q1 2024 financial results indicate a strategic focus on commercialization and cost-efficiency. The company reported gross proceeds of $15.8 million from an equity private placement, including a significant investment from Bio-Rad. This funding is crucial for advancing OncoCyte's product pipeline and expanding its market presence.

Operational efficiency is evident, with OncoCyte reducing its cash burn to $3.9 million, reflecting a capital-efficient business model. The collaboration with Bio-Rad and the anticipated commercial launch of GraftAssure RUO test kits in Asia, the U.S., and the EU are expected to drive revenue growth and broaden the company's market reach. Riggs remarked, "The collaboration with Bio-Rad is pivotal for the upcoming launch of our GraftAssure RUO transplant rejection diagnostic test kit and central to our mission of developing accessible point-of-care diagnostics and continuous innovation in transplant rejection monitoring."

Publication in New England Journal of Medicine

OCX announced a significant milestone on May 30, 2024, with the publication of promising data on VitaGraft Kidney in the New England Journal of Medicine. This phase 2 study highlights VitaGraft Kidneys potential to revolutionize kidney transplant care by accurately monitoring graft health through measuring donor-derived cell-free DNA (dd-cfDNA).

For investors, this development signals substantial market potential. VitaGraft Kidney's ability to monitor therapeutic efficacy and detect disease recurrence opens new revenue streams. This test could become a standard in post-transplant care, driving repeated testing and long-term revenue.

VitaGraft Kidney addresses a critical unmet need. Up to 20.2% of kidney transplant patients develop antibody-mediated rejection (AMR) within 10 years, with no FDA-approved drugs currently available for AMR management. The combination of VitaGraft testing and felzartamab therapy offers a promising solution, potentially improving patient outcomes and healthcare efficiency.

OCX CEO Josh Riggs emphasized the breakthrough nature of this study, stating, This positions VitaGraft Kidney as a crucial tool in managing transplant health. Our recent partnership with Bio-Rad expands our capacity to deliver these innovative solutions globally. Riggs highlighted the tests competitive edge in detecting AMR up to 10 months earlier than current protocols, enhancing patient care, and strengthening OncoCytes market position.

The findings will be presented at the 2024 American Transplant Congress on June 3, 2024. This presentation is expected to further validate VitaGraft Kidneys clinical value and could act as a catalyst for broader market adoption.

OncoCytes latest publication not only validates VitaGraft Kidneys clinical potential but also strengthens the companys market position. As OCX continues to innovate and expand its market reach, investors can anticipate significant growth opportunities in the precision diagnostics sector.

Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by PCG Advisory Inc. to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content.

Contact Details

RazorPitch Inc

Mark McKelvie

+1 585-301-7700

Mark@razorpitch.com

Company Website

http://razorpitch.com

View source version on newsdirect.com: https://newsdirect.com/news/oncocytes-innovative-approach-potential-in-precision-diagnostics-135744794

RazorPitch OCX

comtex tracking

COMTEX_453381299/2655/2024-06-05T07:05:11

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

New Oasis International Foundation (NOIF) – Community Culture & Elder Care Initiative

Published

on

 In December 2025, through the collaborative efforts of the New Oasis International Foundation and its regional partners, a heartwarming initiative was successfully held to honor and support our elderly community, aiming to enhance their overall quality of life.

Guided by our core mission of “Promoting Community Well-being through Care and Culture,” the event sought to provide warmth and support to the elders who have contributed so much to society. During this initiative, volunteers, staff, and community members gathered to create a nurturing and supportive environment for seniors in need.

Event Highlights:

  • Essential Provisions: Distribution of daily necessities to ensure that the fundamental needs of the elderly participants were met.
  • Cultural Engagement: A diverse program featuring traditional dances and interactive games, such as Bingo, bringing joy and a sense of belonging to the participants.
  • Spirit of Unity: Volunteers and staff, identifiable in their signature New Oasis International Foundation vests, served as a visible testament to the spirit of community solidarity and compassion.

This event transcended the mere distribution of goods; it was a profound expression of respect, care, and gratitude toward our elders. The smiles on their faces served as a powerful reminder of the vital importance of communal support.

As the New Oasis International Foundation continues its global expansion, we remain steadfast in our commitment to community-driven, sustainable public welfare projects that empower vulnerable populations. We take great pride in the positive impact this event had on our seniors and look forward to fostering even more meaningful interactions and partnerships in the future.

Media Contact: 

Media Relations
Global News Online
New York
NY
United States
https://www.globalnewsonline.info

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Community Rallies Around Tracey Archer Family Following Sudden Loss of Noah Thomas Archer

Published

on

Crowdfunding Campaign Launched to Support Funeral Expenses and Family Needs After Unexpected Tragedy.

United States, 18th May 2026 – A heartfelt crowdfunding campaign has been launched to support Tracey Archer and her family following the sudden and devastating passing of her husband, Noah Thomas Archer, who unexpectedly passed away on April 21, 2026, at the age of 44.

Noah was known as a devoted husband, loving father, loyal friend, and a deeply cherished member of his community. His unexpected passing has left his family grieving an unimaginable loss while also facing the financial challenges that often accompany sudden tragedy.

The crowdfunding campaign was created to help ease the burden of funeral and memorial expenses, household costs, and ongoing family support during this difficult transition. Beyond financial assistance, the campaign also represents an outpouring of love, compassion, and solidarity from friends, family members, and supporters who want the Archer family to know they are not alone.

Campaign Link: https://gofund.me/601fe2ed4

Tracey Archer has spent years supporting and uplifting others both personally and professionally, and now members of her community are coming together to support her family in return. Organizers say the campaign reflects the importance of community support during life’s most painful moments.

“No one is ever prepared to lose the love of their life so suddenly. Every message, donation, and share reminds our family that we are not alone during the hardest moment of our lives,” said Tracey Archer.

The fundraiser encourages people to contribute in any way they can, through donations, prayers, or simply sharing the campaign with others. Every act of kindness helps provide comfort and stability for the family as they navigate this heartbreaking chapter.

“Noah meant so much to so many people. This campaign is not only about financial support, it’s about honoring his life, his love for his family, and the incredible community standing behind us,” the family shared.

Supporters and well-wishers are invited to visit the campaign page to learn more and contribute toward helping the Archer family during this difficult time.

GoFundMe Campaign: https://gofund.me/601fe2ed4

Media Contact

Organization: Tracey Archer Family

Contact Person: Tracey Archer

Website: https://gofund.me/601fe2ed4

Email: Send Email

Country:United States

Release id:45164

The post Community Rallies Around Tracey Archer Family Following Sudden Loss of Noah Thomas Archer appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

Press Release

Scalpmasters RI Emerges as a Destination Clinic for Scalp Micropigmentation Across New England

Published

on

United States, 18th May 2026 — Scalpmasters – Scalp Micropigmentation Hair Clinic, a Rhode Island-based scalp micropigmentation provider led by Michael Misurelli, continues to attract clients from across the Northeast as demand grows for non-surgical hair loss solutions and natural-looking scalp micropigmentation results.

Located in Cranston, Rhode Island, Scalpmasters RI has built a reputation throughout New England through its full-time focus on scalp micropigmentation (SMP), personalized treatment plans, and consistently positive client experiences. With more than 300 five-star Google reviews and clients regularly traveling from Massachusetts, Connecticut, New Hampshire, Maine, Rhode Island, and New York City, the clinic has become a destination for individuals seeking customized hairline restoration and the appearance of fuller hair.

Unlike many clinics that offer SMP as one of several cosmetic services, Scalpmasters RI focuses exclusively on scalp micropigmentation. The clinic provides SMP services for men and women experiencing thinning hair, alopecia, visible scars, receding hairlines, and other hair loss-related concerns.

As awareness of scalp micropigmentation continues to expand across the United States, more clients are prioritizing trust, artist experience, and natural-looking outcomes over convenience alone. According to reviews published by clients online, many individuals are willing to travel several hours for treatment after researching providers throughout the region.

One client from Central Massachusetts shared in a public review that he researched multiple scalp micropigmentation practitioners before ultimately choosing Scalpmasters RI, adding that the drive was “absolutely worth it.” Another client from Westport, Massachusetts stated that he traveled to see Michael Misurelli after hearing positive feedback from a friend and described the experience as worth every penny.

Additional reviewers referenced traveling more than four hours for appointments, while another client noted that Misurelli’s professionalism and experience made them comfortable commuting approximately 1.5 hours each way for treatment sessions.

This growing trend reflects a broader shift within the scalp micropigmentation industry, where consumers increasingly seek specialists with proven portfolios, strong review histories, and dedicated SMP experience.

“Our focus has always been providing natural-looking scalp micropigmentation results tailored to each client,” said Michael Misurelli, founder of Scalpmasters RI. “People dealing with hair loss often spend a long time researching their options before making a decision. We take that responsibility seriously and work to create an experience where clients feel comfortable, informed, and confident throughout the process.”

Scalp micropigmentation is a non-surgical cosmetic procedure that uses specialized pigmentation techniques to replicate the appearance of hair follicles on the scalp. The treatment is commonly used to create the look of a closely shaved hairstyle, add the appearance of density to thinning hair, soften visible scars, and improve hairline definition. Results vary by individual, and treatment plans are customized based on hair type, skin tone, and desired appearance.

Scalpmasters RI has continued expanding its visibility throughout neighboring states as demand increases for experienced SMP practitioners in the Northeast. Clients searching for Scalp Micropigmentation Rhode Island, Scalp Micropigmentation Massachusetts, and Scalp Micropigmentation Connecticut services have increasingly discovered the clinic through referrals, online reviews, and word-of-mouth recommendations.

The clinic also continues seeing increased interest from individuals searching for Scalp Micropigmentation New England services, particularly among those willing to travel for experienced providers with a strong reputation for consistency and professionalism.

Industry observers note that the growth of scalp micropigmentation in recent years has led to a more informed consumer base. Many prospective clients now spend weeks or months reviewing before-and-after results, researching practitioners, and reading customer feedback before selecting a clinic. As a result, clinics with strong client retention, referral traffic, and verified review histories have gained greater visibility within the market.

Scalpmasters RI’s reputation has also been supported by its emphasis on individualized consultations and customized hairline design rather than one-size-fits-all treatment approaches. According to the company, each procedure is tailored to complement the client’s facial structure, age, hair pattern, and personal goals while maintaining realistic and natural-looking results.

As the company continues serving clients across New England, Misurelli said the clinic remains focused on maintaining quality, consistency, and personalized service as its reputation grows.

“We understand that people are often traveling significant distances because they want a provider they trust,” Misurelli said. “That trust means everything to us, and we’re committed to continuing the level of care and attention that helped build our reputation.”

About Scalpmasters – Scalp Micropigmentation Hair Clinic

Scalpmasters – Scalp Micropigmentation Hair Clinic is a Cranston, Rhode Island-based scalp micropigmentation clinic specializing exclusively in SMP services for men and women. Led by Michael Misurelli, the clinic provides personalized scalp micropigmentation treatments for thinning hair, hairline restoration, alopecia, and scalp scars for clients across Rhode Island and the greater New England region.

Media Contact

Organization: Scalpmasters – Scalp Micropigmentation Hair Clinic

Contact Person: Michael Misurelli

Website: https://www.scalpmastersri.com/

Email: Send Email

Country:United States

Release id:45160

The post Scalpmasters RI Emerges as a Destination Clinic for Scalp Micropigmentation Across New England appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

About Author

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Digi Observer journalist was involved in the writing and production of this article.

Continue Reading

LATEST POST